We are monitoring the impact of COVID-19 on Angina Pectoris Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 8022
Share on
Share on

Global Angina Pectoris Drugs Market Size, Share, Trends, Growth & COVID-19 Impact Analysis Report – Segmented By Therapeutic Class and Region – Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 8022
Pages: 175

Angina Pectoris Drugs Market Size (2021 to 2026)

As per our report, the global angina pectoris drugs market size is estimated to grow at a CAGR of 3.2% from 2021 to 2026.

Angina pectoris is a medical condition identified by precordial heaviness or distress due to temporary myocardial ischemia without infarction, elicited by physical or mental stress. Angina pectoris is classified as - stable, unstable, microvascular, and Prinzmetal. Angina pectoris is an initial symptom of coronary heart disease and significantly affects life quality, costs to society, and workability.

MARKET DRIVERS:

The increase in the number of ischemic heart diseases, the rising geriatric population, and the adoption of a rich, westernized diet, and the subsequent growth of smoking, obesity, and diabetes are significantly driving the global angina development pectoris drugs market.

Several new investigational drugs are being tested to treat chronic angina and reduce currently marketed drugs' side effects. The increased prevalence of cardiovascular diseases and the rise in the geriatric population are driving the market growth. Growing research and development projects in the healthcare segment and augmented healthcare expenditure further expand the angina pectoris drugs market.

The angina pectoris drug market growth is further influenced by the increase in the prevalence of cardiovascular diseases and an increase in the geriatric population. The leading cause of death on the earth is cardiovascular disease. In 2015, 17.7 million people died from heart disease, accounting for 31% of all deaths worldwide. Ischemic heart disease's high prevalence has become a major medical and social concern, creating a market opportunity for market players in all geographies. Synergistic combinations, current clinical trials, and other pharmacological advances, such as novel routes of administration, dosing regimens, and so on, are all trends in the development of antianginal drugs. Increasing healthcare research and development programs and increased healthcare spending are boosting the angina pectoris drugs market forward.

MARKET RESTRAINTS:

Currently, only a few research activities are being conducted specifically to treat angina pectoris. Not many approvals have been granted for the novel compounds in the past few years, limiting the market growth. A majority of patients with chest pain remain undiagnosed with the possibility of suffering from angina or buying generic medicines instead of specific branded medicines, which hampers the demand in the global Angina Pectoris drugs market. Along with this, non-adherence to cardiovascular medications has also been observed among patients suffering from cardiovascular diseases, which may further hinder the market growth.

Ischemic heart disease is the most common cause of death and disability worldwide, and angina is the most common symptom. Angina affects about 9 million people in the United States, and its treatment can be challenging. The changing regulatory landscape in the United States creates a favorable climate for transformative healthcare innovations. The new Clinical Trials Regulation will impact clinical trials of Advanced Therapy Medicinal Products in the EU. Industry worries about innovative therapy ROIs appear to be a challenge to drug development.

Impact of COVID-19 on Angina Pectoris Drugs Market

The Covid-19 pandemic has impacted society and the overall economy across the world and caused uncertainty in the stock market, massive disruption of the supply chain, falling business confidence, and increasing panic among the customer segments. As the different regions' governments have already announced a complete lockdown and temporary closedown of industries, the overall production process is adversely affected, hindering the overall angina pectoris drugs globally.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Therapeutic Class and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This research report on the global angina pectoris drugs market has been segmented and sub-segmented based on the therapeutic class and region.

Angina Pectoris Drugs Market – By Therapeutic Class:

  • Beta-Blockers         
  • Calcium Antagonists          
  • Anticoagulants      
  • Anti-Platelets         
  • Others      

Beta-blockers work by blocking the hormone epinephrine (adrenaline) effects, which causes the heart to beat more slowly and with less force, thus easing the blood pressure. Combining nitrates with beta-blockers is most used to block tachycardia and generating a synergetic anti-ischaemic effect. The Beta-Blocker market now is predominately generic, with key patent expirations impacting GlaxoSmithKline's Coreg and AstraZeneca's Toprol. Post Pfizer's Norvasc patent being determined invalid in 2007, the Calcium Antagonist market is predominantly generic.

A few of the emerging anti-anginal drugs are nicorandil, ivabradine, ranolazine, and trimetazidine.

Angina Pectoris Drugs Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, the global angina pectoris drugs market was dominated by North America in 2019, with an overall market share of over 33% globally. Europe and Asia-Pacific followed North America. North America controls the Angina Pectoris Drugs market is driven by the organized healthcare infrastructure, increased adoption of therapeutics, and key manufacturers in the U.S. responsible for its large share. Ischaemic heart disease is among the significant cause of death and disability worldwide, while angina represents its most common symptom. It is estimated that approximately 9 million patients in the USA suffer from angina and its treatment is challenging. Moreover, the increasing incidence of cardiac disorders due to the sedentary lifestyle and favorable regulatory initiatives fuel market growth. Approximately 9.8 million Americans are estimated to experience angina annually, with 500,000 new angina cases occurring every year.

The European market follows North America, with EU5 leading the market share due to developed medical care facilities and a good reimbursement scenario.

The Asia Pacific is predicted to grow at a rapid pace in the coming few years. Asia Pacific region represents a vast market opportunity for the anti-angina drug market owing to the increasing number of cardiovascular problems and improvising healthcare facilities.

The Middle East and Africa represent the least market share, but a vast market opportunity has been anticipated with the increasing burden of ischemic heart diseases in these regions. Furthermore, Ischemic heart disease is the leading cause of death globally. The vast majority of it occurs outside the high-income world, increasing market opportunities in low- and middle-income countries.  

KEY MARKET PARTICIPANTS:

Some of the key competitors leading the Global Angina Pectoris Drugs Market profiled in this report are Sanofi, Bayer HealthCare, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT), Merck & Co. Inc., Anthera Pharmaceuticals, Cardium Therapeutics, Astellas Pharma, Ark Therapeutics Group plc, Torrent Pharmaceuticals Limited, Circ Pharma Limited, HUYA Bioscience International LLC, Lacer S.A., Viromed Co. Ltd., and Baxter Healthcare Corporation.

RECENT MARKET HAPPENINGS:

  • AstraZeneca and Recordati S.p.A. collaborated in May 2017 to launch Metoprolol succinate; a beta-blocker used to treat angina pectoris.
  • The FDA approved Xarelto (rivaroxaban) in October 2018, and it can be used to treat chronic angina alongside beta-blockers, nitrates, calcium channel blockers, and ACE inhibitors.
  • Kapspargo Sprinkle (metoprolol succinate) extended-release capsules for the treatment of hypertension (high blood pressure), angina pectoris (chest pain), and heart failure were released in the United States on August 6, 2018, according to Sun Pharmaceutical Industries Ltd. (in patients with heart failure, to reduce the risk of cardiovascular mortality and heart-failure hospitalization).
  • 15th of April, 2020 In Wednesday's trading, Dr. Reddy's Laboratories jumped more than 3% after the company announced the launch of an approved generic version of the NitroDur (nitroglycerin) Transdermal Infusion System. Nitro-Dur is used to avoid chest pain attacks (angina), but it does not treat angina that has already started.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapeutic class                     

                                5.1.1 Introduction           

                                5.1.2 Beta blockers         

                                5.1.3 Calcium anatagonists          

                                5.1.4 Anticoagulants      

                                5.1.5 Anti platelets         

                                5.1.6 Others      

                                5.1.7  Y-o-Y Growth Analysis, By therapeutic class            

                                5.1.8  Market Attractiveness Analysis, By therapeutic class          

                                5.1.9 Market Share Analysis, By therapeutic class             

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By therapeutic class

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By therapeutic class

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By therapeutic class

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Anthera Pharmaceuticals                     

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Cardium Therapeutics                            

                8.3 Sanofi                           

                8.4 Bayer HealthCare                     

                8.5 Cardeus Pharmaceuticals                     

                8.6 Ark Therapeutics Group plc                 

                8.7 Torrent Pharmaceuticals Limited                       

                8.8 Circ Pharma Limited                

                8.9 Viromed Co. Ltd.                      

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Therapeutic Class, By Region along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. Global Angina Pectoris drugs Market, By Region, From 2021 to 2026 (USD Million)
  2. Global Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  3. Global Beta blockers Market, By Region, From 2021 to 2026 (USD Million)
  4. Global Calcium antagonists Market, By Region, From 2021 to 2026 (USD Million)
  5. Global Anti coagulants Market, By Region, From 2021 to 2026 (USD Million)
  6. Global Anti platelets Market, By Region, From 2021 to 2026 (USD Million)
  7. Global Others Market, By Region, From 2021 to 2026 (USD Million)
  8. North America Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  9. North America Beta blockers Market, By Region, From 2021 to 2026 (USD Million)
  10. North America Calcium antagonists Market, By Region, From 2021 to 2026 (USD Million)
  11. North America Anti coagulants Market, By Region, From 2021 to 2026 (USD Million)
  12. North America Anti platelets Market, By Region, From 2021 to 2026 (USD Million)
  13. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  14. United States Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  15. Canada Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  16. Europe Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  17. Europe Beta blockers Market, By Region, From 2021 to 2026 (USD Million)
  18. Europe Calcium antagonists Market, By Region, From 2021 to 2026 (USD Million)
  19. Europe Anti coagulants Market, By Region, From 2021 to 2026 (USD Million)
  20. Europe Anti platelets Market, By Region, From 2021 to 2026 (USD Million)
  21. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  22. U.K. Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  23. Germany Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  24. France Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  25. Italy Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  26. Spain Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  27. Asia Pacific Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  28. Asia Pacific Beta blockers Market, By Region, From 2021 to 2026 (USD Million)
  29. Asia Pacific Calcium antagonists Market, By Region, From 2021 to 2026 (USD Million)
  30. Asia Pacific Anti coagulants Market, By Region, From 2021 to 2026 (USD Million)
  31. Asia Pacific Anti platelets Market, By Region, From 2021 to 2026 (USD Million)
  32. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Million)
  33. Japan Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  34. China Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  35. India Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  36. Australia Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  37. South Korea Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  38. Latin America Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  39. Latin America Beta blockers Market, By Region, From 2021 to 2026 (USD Million)
  40. Latin America Calcium antagonists Market, By Region, From 2021 to 2026 (USD Million)
  41. Latin America Anti coagulants Market, By Region, From 2021 to 2026 (USD Million)
  42. Latin America Anti platelets Market, By Region, From 2021 to 2026 (USD Million)
  43. Latin America Others Market, By Region, From 2021 to 2026 (USD Million)
  44. Brazil Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  45. Argentina Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  46. Mexico Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  47. Rest of Latin America Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  48. Middle East and Africa Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  49. Middle East and Africa Beta blockers Market, By Region, From 2021 to 2026 (USD Million)
  50. Middle East and Africa Calcium antagonists Market, By Region, From 2021 to 2026 (USD Million)
  51. Middle East and Africa Anti coagulants Market, By Region, From 2021 to 2026 (USD Million)
  52. Middle East and Africa Anti platelets Market, By Region, From 2021 to 2026 (USD Million)
  53. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Million)
  54. Middle East Angina Pectoris Drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  55. Africa Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample